The CMRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CMRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CMRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CMRX Detailed Price Forecast - CNN Money||View CMRX Detailed Summary - Google Finance|
|View CMRX Detailed Summary - Yahoo! Finance||View CMRX Stock Research & Analysis - Zacks.com|
|View CMRX Trends & Analysis - Trade-Ideas||View CMRX Major Holders - Barrons|
|View CMRX Call Transcripts - NASDAQ||View CMRX Breaking News & Analysis - Seeking Alpha|
|View CMRX Annual Report - CompanySpotlight.com||View CMRX OTC Short Report - OTCShortReport.com|
|View CMRX Fundamentals - TradeKing||View CMRX SEC Filings - Bar Chart|
|View Historical Prices for CMRX - The WSJ||View Performance/Total Return for CMRX - Morningstar|
|View the Analyst Estimates for CMRX - MarketWatch||View the Earnings History for CMRX - CNBC|
|View the CMRX Earnings - StockMarketWatch||View CMRX Buy or Sell Recommendations - MacroAxis|
|View the CMRX Bullish Patterns - American Bulls||View CMRX Short Pain Metrics - ShortPainBot.com|
|View CMRX Stock Mentions - StockTwits||View CMRX Stock Mentions - PennyStockTweets|
|View CMRX Stock Mentions - Twitter||View CMRX Investment Forum News - Investor Hub|
|View CMRX Stock Mentions - Yahoo! Message Board||View CMRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for CMRX - SECform4.com||View Insider Transactions for CMRX - Insider Cow|
|View CMRX Major Holdings Summary - CNBC||View Insider Disclosure for CMRX - OTC Markets|
|View Insider Transactions for CMRX - Yahoo! Finance||View Institutional Holdings for CMRX - NASDAQ|
|View CMRX Stock Insight & Charts - FinViz.com||View CMRX Investment Charts - StockCharts.com|
|View CMRX Stock Overview & Charts - BarChart||View CMRX User Generated Charts - Trading View|
Chimerix to Host Annual Investor Update on October 17, 2018
Posted on Thursday October 11, 2018
DURHAM, N.C., Oct. 11, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host.
How Should You Think About Chimerix Inc’s (NASDAQ:CMRX) Risks?
Posted on Thursday October 11, 2018
If you’re interested in Chimerix Inc (NASDAQ:CMRX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact
Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek
Posted on Friday October 05, 2018
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascending doses (MAD) of intravenous (IV) brincidofovir (BCV) in healthy subjects. “This study shows that four weekly or twice-weekly doses of the IV formulation of brincidofovir are generally well tolerated, and the 10 mg dose provides similar blood levels as the oral 100 mg dose with no reported gastrointestinal side effects,” said Garrett Nichols, MD, MS, Chief Medical Officer of Chimerix.
Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Posted on Thursday October 04, 2018
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the full analysis of adenovirus (AdV) viral load dynamics and all-cause mortality in pediatric patients. Prior to the AdVance study, the epidemiology of AdV after allo-HCT has been generally understood via single-center studies, with little data on the correlation between AdV viral load and risk of mortality. “AdVance represents a significant step forward in our understanding of the impact of adenovirus on allo-HCT recipients.